{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:52:48Z","timestamp":1791319968707,"version":"4.3.1"},"reference-count":5,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2018,12,9]]},"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1136\/gutjnl-2018-317839","type":"journal-article","created":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T17:15:19Z","timestamp":1546017319000},"page":"398-400","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Follow-on rifaximin for the prevention of recurrence following standard treatment of infection with\n                    <i>Clostridium difficile<\/i>\n                    : a competing risks analysis provides a full picture of possible treatment effects"],"prefix":"10.1136","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3088-3513","authenticated-orcid":false,"given":"Maja Katharina","family":"von Cube","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Medical Center, Institute for Medical Biometry and Statistics, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schumacher","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Medical Center, Institute for Medical Biometry and Statistics, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wolkewitz","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Medical Center, Institute for Medical Biometry and Statistics, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,12,28]]},"reference":[{"key":"2025121301345424000_69.2.398.1","doi-asserted-by":"crossref","unstructured":"Major G , Bradshaw L , Boota N , et al . Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with Clostridium Difficile (RAPID): a randomised placebo controlled trial. Gut 2018:316794.doi:10.1136\/gutjnl-2018-316794","DOI":"10.1136\/gutjnl-2018-316794"},{"key":"2025121301345424000_69.2.398.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-017-4802-4"},{"key":"2025121301345424000_69.2.398.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5060"},{"key":"2025121301345424000_69.2.398.4","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/sim.7215","article-title":"Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"key":"2025121301345424000_69.2.398.5","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2017.107"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2018-317839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T09:35:07Z","timestamp":1765618507000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2018-317839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,28]]},"references-count":5,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,1,7]]},"published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1136\/gutjnl-2018-317839"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2018-317839","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,28]]}}}